TITLE

Rx for economic growth

AUTHOR(S)
Kaelble, Steve
PUB. DATE
April 2002
SOURCE
Indiana Business Magazine;Apr2002, Vol. 46 Issue 4, p57
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the launching of Central Indiana Life Sciences Initiative aimed at developing the region as a recognized center for the life sciences industry. Estimate on employment in the industry; Acquisition of investment capital; Creation of a life sciences campus.
ACCESSION #
7146372

 

Related Articles

  • Bio Future: A growing number of promising life sciences companies across the state. Hromadka, Erik // Indiana Business Magazine;Jan2007, Vol. 51 Issue 1, p14 

    The article focuses on the development of life sciences companies across Indiana. It has been stressed that there are many smaller companies leading the life sciences industry's future though it is often considered in terms of world-leading companies. The state has taken steps to aid the growth...

  • CAPITAL IN AGRICULTURE. Wilcox, Walter W. // Quarterly Journal of Economics;Nov43, Vol. 58 Issue 1, p49 

    This article examines the nature of the capital investment problem in agriculture in the U.S. Throughout this decade the most heated debates regarding the functioning of capital in the economy will center around the appropriate role of the government in investments and capital formation....

  • Integra LifeSciences raises $5 million equity investment. Rosa, Taina // Caribbean Business;10/19/2000, Vol. 28 Issue 41, p6 

    Reports that New Jersey-based Integra LifeSciences will inject $5 million into its global operations which benefit its plant in Anasco, Puerto Rico. Number of shares of Integra's common stock issued to strategic investor ArthroCare Corp.; Medical products manufactured by the Anasco plant.

  • Capital Expenditures for Emerging Technologies.  // Bioscience Technology;Apr2008 Supplement, Vol. 33, p23 

    Several charts are presented which show the capital expenditures for emerging technologies in life sciences such as age and capabilities of institution as determinant of degree of capital expenditures, and the changes that will require innovative ventures and type of technologies.

  • Critical mass elusive after years of effort. Wall, J. K. // Indianapolis Business Journal;5/12/2014, Vol. 35 Issue 11, p13 

    The article focuses on the status of life sciences companies in Indiana. Topics discussed include the increasing investment capital for health-related businesses, business tracking conducted by BioEnterprise, a Cleveland-based business development group, for health company-related investments,...

  • Life Sciences Venture Capital Investment Level Rebounds in Q1 2011 but Deal Volume Declines, According to the MoneyTree Report.  // Biomedical Market Newsletter;5/9/2011, p532 

    The article presents information on a new PwC U.S. report entitled "A Case for Cautious Optimism," which shows that life sciences venture capital investment level rebounds in the first quarter of 2011 but deal volume declines. The report is based on data from the PricewaterhouseCoopers...

  • Sweden leads EU in developing new antibiotics. Webster, Paul Christopher // CMAJ: Canadian Medical Association Journal;2/4/2014, Vol. 186 Issue 2, pE84 

    The article discusses the role of Sweden in antibiotic development as of February 2014. Topics discussed include the announcement by Swedish government in 2013 that it would double its investment in life science through 2016, the start of Sweden's leadership in antibiotic control in 1986, and...

  • Working double hard. Rao, Ch. Srinivas // BioSpectrum;Jul2013, Vol. 11 Issue 7, p86 

    The author discusses the growth of the bioscience industry in India as of 2013. Topics include the comparative growth of the bioscience sector and Indian life sciences industry known as BioSuppliers, the need for mandatory corporate practice of higher capital investments to maintain the growth...

  • Sofinnova Closes $312M 7th Fund; Bets on Life Sciences. Sheridan, Cormac // BioWorld International;12/12/2012, Vol. 17 Issue 50, p1 

    The article reports on the seventh fund raised by Sofinnova Partners for its research on life sciences in 2012. The firm succeeded in raising 312 million U.S. dollars from the round. Managing partner Antoine Papiernik acknowledged the difficulty in raising the money. The company's compounded...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics